Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Letrozole, and Palbociclib in Metastatic ER+ Breast Cancer
NCT02778685Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Sep 2016
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in breast cancer, sponsored by City of Hope. Started Sep 2016; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02778685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02778685.